Novel Treatments for Alzheimer’s Disease
International Clinical Neuroscience Journal,
Vol. 4 No. 2 (2017),
12 June 2017
,
Page 39-45
https://doi.org/10.22037/icnj.v4i2.17105
Abstract
Alzheimer’s disease (AD) is a multifarious neurodegenerative disorder that leads to cognitive impairment and dementia in late adult life. Pathology hallmarks of Alzheimer’s disease were observed intracellular neurofibrillary tangles and extracellular amyloidal protein. According to pathology of this disease, abundant studies were performed with focused on pharmacological therapeutics over the last two decades. Current treatments for AD are acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate receptor antagonist (memantine) that can decrease the progression of the disease. In this review, authors will discuss the various aspects of pathophysiological mechanisms and therapeutic strategies of Alzheimer’s disease.
How to Cite
References
Alzheimer A. Uber eine eigenartige Erkrankung der Hirnridne [About a Peculiar Disease of the Cerebral Cortex]. Allg Z Psychiatr 1907; 64: 146-48.
Alzheimer A. About a peculiar disease of the cerebral cortex. Alzheimer Dis Assoc Disord 1987; 1: 3-8.
Maurer K, Volk S, Gerbaldo H. Auguste D. Alzheimer’s disease. Lancet 1997; 349: 1546_9.
Serretti A, Olgiati P, De Ronchi D. Genetics of Alzheimer’s disease. A rapidly evolving field. J Alzheimers Dis. 2007;12:73-92.
Hiltunen M, Lu A, Thomas AV, Romano DM, Kim M, Jones PB. Ubiquilin 1 modulates amyloid precursor protein trafficking and amyloid-β secretion. J Biol Chem. 2006;281:32240-32253.
Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, et al. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer’s disease brain. Neurobiol Aging. 2005;26:795-802.
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704-706.
Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics and proteomics of Alzheimer’s disease. J Clin Psychiatry. 2006;67:652-670.
Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120: 388-397.
Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-Daspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol. 2006; 17: 411–24.
Mann DM. Pyramidal nerve cell loss in Alzheimer’s disease. Neurodegeneration. 1996;5: 423-7.
Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789-91.
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329-44.
Norfray JF, Provenzale JM. Alzheimer’s disease: neuropathologic findings and recent advances in imaging. AJR Am J Roentgenol. 2004;182:3-13.
Vetrivel KS, Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology. 2006;66:S69-73.
Dal Pra` I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, Gardenal E, et al. Do astrocytes collaborate with neurons in spreading the ‘‘infectious’’ Ab and tau drivers of Alzheimer’s disease? Neuroscientist. 2014; 21:9-29.
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70: 960_9.
Camicioli R. Distinguishing different dementias. Can Rev Alzheimer’s Dis Other Dement. 2006; 9: 4_11.
Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56: 1143_53.
Ghosh AK, Brindisi M, Tang J. Developing b-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120(1):71–83.
Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer’s disease, A beta peptide neurotoxicity. Neurochem Res. 2008; 33: 526-532.
Vlad SC, Miller DR, Kowall NW, Felson DT Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008; 70: 1672-1677.
Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimer’s disease. Expert Opin Ther Targets. 2008; 12: 693-704.
Bue´e L, Bussiere T, Bue´ e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33(1):95–130.
Engel T, Gon˜i-Oliver P, Lucas JJ, Avila J, Herna´ndez F. Chronic lithium administration to FTDP-17 tau and GSK-3b overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006;99(6):1445–55.
Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.
Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120: 388-397.
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271:992–8.
Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem. 2012;120:22–33.
Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid b 1–40. Eur J Pharmacol. 2012;692:38–45.
Rissman RA, De Blas AL, Armstrong DM. GABAA receptors in aging and 801 Alzheimer’s disease. J Neurochem. 2007;103:1285–92. 802
Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, et al. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid 806 precursor protein processing. J Neurochem. 2008;106:392–404.
Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol. 2012;99:15–41. 821
King MV, Marsden CA, Fone KC. A role for the 5-HT 1A, 5-HT 4 and 5-HT 6 receptors in learning and memory. Trends Pharmacol Sci. 2008;29: 823 482–92.
Patat A, Parks V, Raje S, Plotka A, Chassard D, Coz FL. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br J Clin Pharmacol. 2009;67:299–308.
Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, et al. SB- 829 742457 and donepezil in Alzheimer disease: a randomized, placebo-con- 830 trolled study. Int J Geriatr Psychiatry. 2011;26:536–44.
Gravius A, Laszy J, Pietraszek M, Saghy K, Nagel J, Chambon C, et al. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detec- tion of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol. 2011;22:122–35.
Tillement L, Lecanu L, Papadopoulos V. Alzheimer’s disease: effects of β-amyloid on mitochondria. Mitochondrion. 2011;11:13-21.
Behl C. Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301-323.
Perrig WJ, Perrig P, Stähelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc. 1997;45:718-724.
Tauskela JS. MitoQ--a mitochondria-targeted antioxidant. Drugs. 2007;10:399-412.
Lee J, Boo JH, Ryu H. The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv Drug Deliv Rev. 2009;61(14): 862 1316–23.
Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebro-spinal fluid biomarker measures. Arch Neurol. 2012;69(7):836–41.
Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-b toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20:609–31.
Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al. Complete rescue of cerebrovascular function in aged Alzheimer’s 888 disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist. J Neurosci. 2008;28(37):9287–96.
Lichtenstein MP, Carriba P, Baltrons MA, Wojciak-Stothard B, Peterson JR, Garcı´a A, et al. Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives. J Alzheimers Dis. 2010;22(4):1135–55.
Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008 Jun 12;453(7197):925-9.
Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci. 2003;1007:64-78.
Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C. Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes. Neuroscience. 2005; 132: 581-589.
Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med. 1993;159: 579-585.
Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001;177:125-134.
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012; 122: 1316-1338.
Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R, et al. Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology. 2013; 154: 375-387.
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012; 64: 614-628.
Shin J-W, Lee JK, Lee JE, Min W-K, Schuchman EH, Jin HK, Bae J. Combined Effects of Hematopoietic Progenitor Cell Mobilization from Bone Marrow by Granulocyte Colony Stimulating Factor and AMD3100 and Chemotaxis into the Brain Using Stromal Cell-Derived Factor-1a in an Alzheimer’s Disease Mouse Model. Stem cells. 2011; 29:1075-1089.
Kim J-Y, Kim DH, Kim JH, Lee D, Jeon HB, Kwon S-J, Kim SM, Yoo YJ, Lee EH, Choi SJ, Seo SW, Lee JI, Na DL, Yang YS, Oh W, Chang JW. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood derived mesenchymal stem cell reduces amyloid-b plaques. Cell Death Differ. 2012; 19: 680-691.
Bae JS, Jin HK, Lee JK, Richardson JC, Carter JE. Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-ß deposits and the improvement of synaptic transmission in a mouse model of predementia Alzheimer’s disease. Curr Alzheimer Res. 2013; 10:524-531.
Park D, Joo SS, Kim TK, Lee SH, Kang H, Lee HJ, et al. Human neural stem cells overexpressing choline acetyltransferase restore cognitive function of kainic acid-induced learning and memory deficit animals. Cell Transplant. 2012; 21: 365-371.
Lee HJ, Lim IJ, Park SW, Ko YB, Kim SU. Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in mouse with ibotenic acid-induced cognitive dysfunction. Cell Transplant. 2012; 21:2487-2496.
Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001;22: 248-291.
Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, et al. Luteinizing hormone modulates cognition and amyloid ß deposition in Alzheimer APP transgenic mice. Biochim. Biophys Acta. 2006; 1762: 447 -452.
Mehta R, Templeton DM, O’brien PJ. Mitochondrial involvement in genetically determined transition metal toxicity II. Copper toxicity. Chem Biol Interact. 2006;163: 77-85.
Squitti R, Polimanti R. Copper hypothesis in the missing hereditability of sporadic Alzheimer’s disease: ATP7B gene as potential harbor of rare variants. J Alzheimers Dis. 2012; 29: 493-501.
Brewer GJ. Copper toxicity in Alzheimer’s disease: cognitive loss from ingestion of inorganic copper. J Trace Elem Med Biol. 2012;26: 89-92.
- Abstract Viewed: 660 times
- PDF Downloaded: 501 times